BNP Paribas Financial Markets
ENTX icon

BNP Paribas Financial Markets’s Entera Bio ENTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio ENTX Stock Details ENTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$708 Buy
+400
New +$500 ﹤0.01% 5639

Other funds holding ENTX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $606M AUM
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

BNP Paribas Financial Markets's ENTX Position: Q2 2026 in Review

BNP Paribas Financial Markets opened a new position in Entera Bio (ENTX) in Q2 2026: 400 shares worth $708. The stake represents ﹤0.01% of the portfolio and ranks #5639 among its holdings.

27 funds tracked by Wall St. Rank hold ENTX as of Q2 2026.

  • BNP Paribas Financial Markets held 400 shares of Entera Bio worth $708 as of Q2 2026.
  • Entera Bio was a new BNP Paribas Financial Markets position in Q2 2026.
  • Entera Bio made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5639 holding.
  • 27 funds tracked by Wall St. Rank held Entera Bio as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.